{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:39:30Z","timestamp":1788068370256,"version":"build-2784847793"},"reference-count":93,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Benzodiazepine acute withdrawal syndrome is well known, but the long-term neurological consequences of benzodiazepine exposure are much less familiar. A scoping review was conducted of electronic databases for studies that reported on patient outcomes four or more weeks after complete cessation of benzodiazepine use. Forty-six results were retrieved in total, some of which provided signals for protracted symptoms, often reported as incidental findings, and others that showed benzodiazepine discontinuation was beneficial. Some overlap occurred in the outcomes, but these two groups of studies suggest that the benefits of benzodiazepine discontinuation for many patients tended to obscure the more prolonged, severe, and sometimes debilitating symptoms that persisted for months and years in a subpopulation of patients. The prevalence or trajectory of these enduring symptoms could not be determined from these studies. Further elucidation of the potential neurotoxicity of benzodiazepines is needed to better understand protracted symptoms and their treatment. Clinicians, patients, and the healthcare system must be cognizant of the risks of benzodiazepine exposure beyond two to four weeks.<\/jats:p>","DOI":"10.1371\/journal.pone.0330277","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:25:18Z","timestamp":1756401918000},"page":"e0330277","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term neurological consequences following benzodiazepine exposure: A scoping review"],"prefix":"10.1371","volume":"20","author":[{"given":"Kyla N.","family":"Shade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0440-1894","authenticated-orcid":true,"given":"Alexis D.","family":"Ritvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-0668","authenticated-orcid":true,"given":"Bernard","family":"Silvernail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. Reid","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3256-5689","authenticated-orcid":true,"given":"Jolene E.","family":"Bressi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-1024","authenticated-orcid":true,"given":"D. E.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1865-0533","authenticated-orcid":true,"given":"Ian J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-4741","authenticated-orcid":true,"given":"Peter R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"pone.0330277.ref001","first-page":"309","volume-title":"Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal","author":"D Foster","year":"2018"},{"issue":"4","key":"pone.0330277.ref002","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.janxdis.2011.01.002","article-title":"The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs","volume":"25","author":"F Lopez-Munoz","year":"2011","journal-title":"J Anxiety Disord"},{"key":"pone.0330277.ref003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00429621","article-title":"Withdrawal reactions from chlordiazepoxide (\u201cLibrium\u201d)","volume":"2","author":"L Hollister","year":"1961","journal-title":"Psychopharmacologia"},{"issue":"19","key":"pone.0330277.ref004","first-page":"1011","article-title":"Drug therapy. Benzodiazepines (first of two parts)","volume":"291","author":"DJ Greenblatt","year":"1974","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0330277.ref005","first-page":"1239","article-title":"Drug therapy. Benzodiazepines (second of two parts)","volume":"291","author":"DJ Greenblatt","year":"1974","journal-title":"N Engl J Med"},{"key":"pone.0330277.ref006","unstructured":"Use and misuse of benzodiazepines: Examination on the use and misuse of Valium, Librium, and other minor tranquilizers: Hearing before the Subcommittee on Health and Science Research of the Committee on Labor and Human Resources United States Senate, U.S. Senate, 96th Congress Sess. 1979."},{"issue":"9","key":"pone.0330277.ref007","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"The discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"DT Wong","year":"2005","journal-title":"Nature Reviews Drug Discovery"},{"issue":"4","key":"pone.0330277.ref008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","article-title":"Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research","volume":"17","author":"J Brandt","year":"2017","journal-title":"Drugs R D"},{"issue":"1","key":"pone.0330277.ref009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0149-7634(85)90038-7","article-title":"Time course for development of benzodiazepine tolerance and physical dependence","volume":"9","author":"HC Rosenberg","year":"1985","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"pone.0330277.ref010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpt1979262256","article-title":"Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach","volume":"26","author":"PR Martin","year":"1979","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"pone.0330277.ref011","first-page":"260","article-title":"Benzodiazepine Use Disorder: Common Questions and Answers","volume":"108","author":"S Robertson","year":"2023","journal-title":"Am Fam Physician"},{"key":"pone.0330277.ref012","first-page":"1","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey","volume":"2","author":"A Finlayson","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"pone.0330277.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285584","article-title":"Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey","volume":"18","author":"AD Ritvo","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"pone.0330277.ref014","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1360-0443.1987.tb01529.x","article-title":"Benzodiazepine withdrawal: outcome in 50 patients","volume":"82","author":"H Ashton","year":"1987","journal-title":"Br J Addict"},{"key":"pone.0330277.ref015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","article-title":"Protracted withdrawal syndromes from benzodiazepines","volume":"8","author":"H Ashton","year":"1991","journal-title":"J Subst Abuse Treat"},{"issue":"6424","key":"pone.0330277.ref016","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/bmj.288.6424.1135","article-title":"Benzodiazepine withdrawal: an unfinished story","volume":"288","author":"H Ashton","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"pone.0330277.ref017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0447.1990.tb01375.x","article-title":"The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria?","volume":"82","author":"A Higgitt","year":"1990","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"pone.0330277.ref018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: a meta-analysis","volume":"18","author":"MJ Barker","year":"2004","journal-title":"CNS Drugs"},{"issue":"12","key":"pone.0330277.ref019","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited--will we ever learn?","volume":"106","author":"M Lader","year":"2011","journal-title":"Addiction"},{"issue":"2","key":"pone.0330277.ref020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12023","article-title":"Benzodiazepine dependence and its treatment with low dose flumazenil","volume":"77","author":"SD Hood","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0330277.ref021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.psychres.2012.02.008","article-title":"High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam","volume":"198","author":"G Quaglio","year":"2012","journal-title":"Psychiatry Res"},{"issue":"3","key":"pone.0330277.ref022","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The diagnosis and management of benzodiazepine dependence","volume":"18","author":"H Ashton","year":"2005","journal-title":"Curr Opin Psychiatry"},{"key":"pone.0330277.ref023","first-page":"1","article-title":"Enduring neurological sequelae of benzodiazepine use: an Internet survey","volume":"12","author":"C Huff","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"pone.0330277.ref024","doi-asserted-by":"crossref","unstructured":"Shade K, Ritvo A, Silvernail B, Martin P, Foster D, Huff C, et al. Benzodiazepine induced neurological dysfunction: an overview of adverse long-term neurological consequences following chronic use of benzodiazepines: a scoping review protocol. 2023.","DOI":"10.1371\/journal.pone.0285584"},{"issue":"7","key":"pone.0330277.ref025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0330277.ref026","doi-asserted-by":"crossref","first-page":"953","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols","volume":"20","author":"MDJ Peters","year":"2022","journal-title":"JBI Evid Synth"},{"key":"pone.0330277.ref027","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0330277.ref028","author":"A Amirzadeh-Shams","year":"2018"},{"issue":"3","key":"pone.0330277.ref029","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1355617705050332","article-title":"An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use","volume":"11","author":"MJ Barker","year":"2005","journal-title":"J Int Neuropsychol Soc"},{"issue":"14","key":"pone.0330277.ref030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1056\/NEJM198610023151403","article-title":"Withdrawal reaction after long-term therapeutic use of benzodiazepines","volume":"315","author":"U Busto","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0330277.ref031","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00004714-198810000-00010","article-title":"Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines","volume":"8","author":"U Busto","year":"1988","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"pone.0330277.ref032","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0924-9338(96)84786-9","article-title":"A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome","volume":"11","author":"G Cassano","year":"1996","journal-title":"Eur Psychiatry"},{"issue":"4","key":"pone.0330277.ref033","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1017\/S0033291700029056","article-title":"Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder","volume":"24","author":"HV Curran","year":"1994","journal-title":"Psychol Med"},{"issue":"1","key":"pone.0330277.ref034","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199502000-00003","article-title":"Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study","volume":"15","author":"R Delle Chiaie","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"pone.0330277.ref035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.2044-8341.1987.tb02724.x","article-title":"A follow-up study of patients treated for benzodiazepine dependence","volume":"60","author":"S Golombok","year":"1987","journal-title":"Br J Med Psychol"},{"issue":"2","key":"pone.0330277.ref036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1017\/S0033291700007911","article-title":"Cognitive impairment in long-term benzodiazepine users","volume":"18","author":"S Golombok","year":"1988","journal-title":"Psychological medicine"},{"issue":"3","key":"pone.0330277.ref037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004850-199409000-00002","article-title":"Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users","volume":"9","author":"C Gorenstein","year":"1994","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"pone.0330277.ref038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/026988119500900404","article-title":"Impairment of performance associated with long-term use of benzodiazepines","volume":"9","author":"C Gorenstein","year":"1995","journal-title":"J Psychopharmacol"},{"key":"pone.0330277.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000412","article-title":"The natural history of tolerance to the benzodiazepines","volume":"13","author":"A Higgitt","year":"1988","journal-title":"Psychol Med Monogr Suppl"},{"issue":"245","key":"pone.0330277.ref040","first-page":"758","article-title":"Benzodiazepine withdrawal in general practice","volume":"32","author":"DR Hopkins","year":"1982","journal-title":"J R Coll Gen Pract"},{"issue":"7","key":"pone.0330277.ref041","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/070674378803300709","article-title":"Delusional depression following benzodiazepine withdrawal","volume":"33","author":"MS Keshavan","year":"1988","journal-title":"Can J Psychiatry"},{"issue":"1","key":"pone.0330277.ref042","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S003329179800734X","article-title":"Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia\/panic patients","volume":"29","author":"C Kili\u00e7","year":"1999","journal-title":"Psychol Med"},{"issue":"2","key":"pone.0330277.ref043","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0033-3182(97)71493-2","article-title":"Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression","volume":"38","author":"JG Modell","year":"1997","journal-title":"Psychosomatics"},{"issue":"4","key":"pone.0330277.ref044","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/026988119500900407","article-title":"Buspirone treatment as an aid to benzodiazepine withdrawal","volume":"9","author":"S Morton","year":"1995","journal-title":"J Psychopharmacol"},{"key":"pone.0330277.ref045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1192\/bjp.154.4.529","article-title":"Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks\u2019 treatment with diazepam or buspirone","volume":"154","author":"SM Murphy","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"2","key":"pone.0330277.ref046","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/026988119601000204","article-title":"Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study","volume":"10","author":"GH O\u2019Sullivan","year":"1996","journal-title":"J Psychopharmacol"},{"issue":"4","key":"pone.0330277.ref047","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/S0033291700019899","article-title":"Depression following withdrawal from long-term benzodiazepine use: a report of four cases","volume":"14","author":"D Olajide","year":"1984","journal-title":"Psychol Med"},{"issue":"4","key":"pone.0330277.ref048","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00427575","article-title":"Psychometric performance during withdrawal from long-term benzodiazepine treatment","volume":"81","author":"H Petursson","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"pone.0330277.ref049","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1991.01810290060012","article-title":"Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome","volume":"48","author":"E Schweizer","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"pone.0330277.ref050","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s12325-022-02055-y","article-title":"Surviving Benzodiazepines: A Patient\u2019s and Clinician\u2019s Perspectives","volume":"39","author":"CM Silvernail","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0330277.ref051","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S0033291700026969","article-title":"Lack of cognitive recovery following withdrawal from long-term benzodiazepine use","volume":"24","author":"PR Tata","year":"1994","journal-title":"Psychol Med"},{"issue":"8339","key":"pone.0330277.ref052","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0140-6736(83)92355-3","article-title":"Gradual withdrawal of diazepam after long-term therapy","volume":"1","author":"P Tyrer","year":"1983","journal-title":"Lancet"},{"issue":"4","key":"pone.0330277.ref053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/070674378302800412","article-title":"Abstinence syndrome from therapeutic doses of oxazepam","volume":"28","author":"R Wilbur","year":"1983","journal-title":"Can J Psychiatry"},{"key":"pone.0330277.ref054","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1192\/bjp.157.2.232","article-title":"A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users","volume":"157","author":"CH Ashton","year":"1990","journal-title":"Br J Psychiatry"},{"issue":"2","key":"pone.0330277.ref055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1037\/0278-6133.27.2.239","article-title":"Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy","volume":"27","author":"G Belleville","year":"2008","journal-title":"Health Psychol"},{"issue":"10","key":"pone.0330277.ref056","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00228-014-1725-7","article-title":"Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study","volume":"70","author":"J Bourgeois","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0330277.ref057","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.156.3.406","article-title":"Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal","volume":"156","author":"T Cantopher","year":"1990","journal-title":"Br J Psychiatry"},{"issue":"7","key":"pone.0330277.ref058","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1017\/S0033291703008213","article-title":"Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life","volume":"33","author":"HV Curran","year":"2003","journal-title":"Psychol Med"},{"issue":"3","key":"pone.0330277.ref059","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.addbeh.2004.01.001","article-title":"Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication","volume":"29","author":"KP O\u2019Connor","year":"2004","journal-title":"Addict Behav"},{"issue":"4","key":"pone.0330277.ref060","first-page":"171","article-title":"The discontinuation of lorazepam and diazepam following sub-chronic therapy in anxious outpatients","volume":"6","author":"P Peperkamp","year":"1993","journal-title":"J Drug Dev"},{"issue":"6292","key":"pone.0330277.ref061","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.283.6292.643","article-title":"Withdrawal from long-term benzodiazepine treatment","volume":"283","author":"H Petursson","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"10","key":"pone.0330277.ref062","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation","volume":"47","author":"K Rickels","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"pone.0330277.ref063","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1176\/ajp.148.6.757","article-title":"Long-term benzodiazepine users 3 years after participation in a discontinuation program","volume":"148","author":"K Rickels","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"2","key":"pone.0330277.ref064","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00004714-199904000-00003","article-title":"Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation","volume":"19","author":"K Rickels","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"pone.0330277.ref065","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1001\/archpsyc.1990.01810220024003","article-title":"Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper","volume":"47","author":"E Schweizer","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"pone.0330277.ref066","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.1995.tb09786.x","article-title":"Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients","volume":"91","author":"U T\u00f6nne","year":"1995","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"pone.0330277.ref067","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/08039481003624173","article-title":"Benzodiazepine tapering: a prospective study","volume":"64","author":"B Vikander","year":"2010","journal-title":"Nord J Psychiatry"},{"issue":"4","key":"pone.0330277.ref068","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0269881111405360","article-title":"Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial","volume":"26","author":"SJ Hadley","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"3","key":"pone.0330277.ref069","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/026988119200600303","article-title":"A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal","volume":"6","author":"MH Lader","year":"1992","journal-title":"J Psychopharmacol"},{"issue":"2","key":"pone.0330277.ref070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199804000-00004","article-title":"A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation","volume":"18","author":"MK Romach","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"pone.0330277.ref071","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.182.6.498","article-title":"Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial","volume":"182","author":"RCO Voshaar","year":"2003","journal-title":"Br J Psychiatry"},{"key":"pone.0330277.ref072","first-page":"308","article-title":"Pharmacology of drugs of abuse.","volume-title":"Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy","author":"P Martin","year":"2017","edition":"4"},{"issue":"4","key":"pone.0330277.ref073","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cpt1977214497","article-title":"Acute overdosage with benzodiazepine derivatives","volume":"21","author":"DJ Greenblatt","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0330277.ref074","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/JCP.0b013e31817efbac","article-title":"Physician Withdrawal Checklist (PWC-20)","volume":"28","author":"K Rickels","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"pone.0330277.ref075","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/joor.13102","article-title":"Evaluation of the efficacy of treatment modalities in burning mouth syndrome-A systematic review","volume":"47","author":"Z \u015alebioda","year":"2020","journal-title":"J Oral Rehabil"},{"issue":"6","key":"pone.0330277.ref076","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/odi.12422","article-title":"Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis","volume":"22","author":"Y Cui","year":"2016","journal-title":"Oral Dis"},{"issue":"23","key":"pone.0330277.ref077","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000954","article-title":"A Case of Stiff Person Syndrome: Immunomodulatory Effect of Benzodiazepines: Successful Rituximab and Tizanidine Therapy","volume":"94","author":"P Zdziarski","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"pone.0330277.ref078","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2020.05.028","article-title":"rTMS and tDCS for the treatment of catatonia: A systematic review","volume":"222","author":"M Hansbauer","year":"2020","journal-title":"Schizophr Res"},{"key":"pone.0330277.ref079","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S147897","article-title":"Systematic review of catatonia treatment","volume":"14","author":"AC Pelzer","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"pone.0330277.ref080","article-title":"Recent advances and review on treatment of stiff person syndrome in adults and pediatric patients","volume":"7","author":"AB Bhatti","year":"2015","journal-title":"Cureus"},{"issue":"11","key":"pone.0330277.ref081","first-page":"759","article-title":"Pharmacological treatment of insomnia","volume":"40","author":"JD Lie","year":"2015","journal-title":"P T"},{"issue":"6","key":"pone.0330277.ref082","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000353198","article-title":"Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis","volume":"82","author":"E Offidani","year":"2013","journal-title":"Psychother Psychosom"},{"issue":"1","key":"pone.0330277.ref083","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1381612023396681","article-title":"Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal","volume":"8","author":"AN Bateson","year":"2002","journal-title":"Curr Pharm Des"},{"issue":"1","key":"pone.0330277.ref084","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-199448010-00004","article-title":"Guidelines for the rational use of benzodiazepines. When and what to use","volume":"48","author":"H Ashton","year":"1994","journal-title":"Drugs"},{"issue":"1","key":"pone.0330277.ref085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0149-7634(85)90038-7","article-title":"Time course for development of benzodiazepine tolerance and physical dependence","volume":"9","author":"HC Rosenberg","year":"1985","journal-title":"Neurosci Biobehav Rev"},{"issue":"11","key":"pone.0330277.ref086","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","article-title":"The benzodiazepine withdrawal syndrome","volume":"89","author":"H P\u00e9tursson","year":"1994","journal-title":"Addiction"},{"key":"pone.0330277.ref087","author":"L Eagles","year":"2008"},{"issue":"5","key":"pone.0330277.ref088","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"J Brett","year":"2015","journal-title":"Aust Prescr"},{"key":"pone.0330277.ref089","unstructured":"Brunner E, Chen CYA, Klein T. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/guidelines\/benzodiazepine-tapering-2025\/bzd-tapering-document---final-approved-version-for-distribution-02-28-25.pdf?sfvrsn=5bdf9c81_3"},{"key":"pone.0330277.ref090","year":"2024"},{"key":"pone.0330277.ref091","doi-asserted-by":"crossref","first-page":"172873","DOI":"10.1016\/j.pbb.2020.172873","article-title":"The long-term but not short-term use of benzodiazepine impairs motoric function and upregulates amyloid \u03b2 in part through the suppression of translocator protein","volume":"191","author":"ME Jung","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"pone.0330277.ref092","doi-asserted-by":"crossref","first-page":"777404","DOI":"10.3389\/fnagi.2021.777404","article-title":"Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice","volume":"13","author":"T Furukawa","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"pone.0330277.ref093","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.283","article-title":"Chronic diazepam administration increases the expression of Lcn2 in the CNS","volume":"5","author":"T Furukawa","year":"2017","journal-title":"Pharmacol Res Perspect"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:25:32Z","timestamp":1756401932000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330277"}},"subtitle":[],"editor":[{"given":"Hira","family":"Rafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":93,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330277","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}